Re: Common misconception about data exclusivity in Fob legislation
If you lower the rewards, then biotech companies will be focused on only those projects they think have a high likely hood of success, and their ratio of wins to losses will improve and they will quit wasting so much of investors money.
It’s a misconception that the data-exclusivity period specified in pending FoB legislation will strongly affect biotech innovation one way or the other.
Biologics approved by the FDA almost always have a remaining patent life at the time of approval that exceeds the longest data-exclusivity periods being considered by Congress; in other words, data exclusivity will hardly ever be the force that limits competition for a branded biologic unless the patent on the biologic in question is flawed.
p.s. You’re not the only poster on this board to miss this point—drbio did it in #msg-39546041.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.